Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism

•An engineered CD300a agonist ligand (CD300a TASR) universally protects HLA-deficient allogeneic T cells from NK cell–mediated rejection.•CD300a TASR enhances chimeric antigen receptor (CAR) T cell efficacy under allogeneic immune pressure. [Display omitted] Immunogenicity limits the persistence of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2025-01, Vol.9 (2), p.254-264
Hauptverfasser:	Zhang, Shu-Qi, Thomas, Faith, Fang, Justin, Austgen, Kathryn, Cowan, Chad, Welstead, G. Grant
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD - metabolism Cell- and Tissue-Based Therapy - methods Humans Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Receptors, Immunologic - metabolism T-Lymphocytes - immunology T-Lymphocytes - metabolism Transplantation, Homologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!